Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.30 ▲ +0.00
(0.00%)
MKT CAP: $120.5M • VOL: 900.2K
52W L $1 52W H $8
ROARABLE / RQD
D • 48/100
PIOTROSKI
1 / 9
AVXL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$51.4M | -$52.9M | -$55.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$46.4M | -$43.0M | -$47.5M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$39.0M | -$30.8M | -$27.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$39.0M | -$30.8M | -$27.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $131.7M | $120.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $126.6M | $110.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AVXL.